Evidence map›Paper›PMID 27472373›Full record

ReviewJournal of clinical medicine2016

Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data.

Paola Bozzatello, Elena Brignolo, Elisa De Grandi, Silvio Bellino

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 8 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 8 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology.International journal of molecular sciences · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Association of dietary long-chainThe British journal of nutrition · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paola BozzatelloCentre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. paola.bozzatello@unito.it.
Elena BrignoloCentre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. elena.brignolo@yahoo.com.
Elisa De GrandiCentre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. elisa.degrandi@gmail.com.
Silvio BellinoCentre for Personality Disorders, Department of Neuroscience, University of Turin, 10126 Turin, Italy. silvio.bellino@unito.it.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new application for omega-3 fatty acids has recently emerged, concerning the treatment of several mental disorders. This indication is supported by data of neurobiological research, as highly unsaturated fatty acids (HUFAs) are highly concentrated in neural phospholipids and are important components of the neuronal cell membrane. They modulate the mechanisms of brain cell signaling, including the dopaminergic and serotonergic pathways. The aim of this review is to provide a complete and updated account of the empirical evidence of the efficacy and safety that are currently available for omega-3 fatty acids in the treatment of psychiatric disorders. The main evidence for the effectiveness of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been obtained in mood disorders, in particular in the treatment of depressive symptoms in unipolar and bipolar depression. There is some evidence to support the use of omega-3 fatty acids in the treatment of conditions characterized by a high level of impulsivity and aggression and borderline personality disorders. In patients with attention deficit hyperactivity disorder, small-to-modest effects of omega-3 HUFAs have been found. The most promising results have been reported by studies using high doses of EPA or the association of omega-3 and omega-6 fatty acids. In schizophrenia, current data are not conclusive and do not allow us either to refuse or support the indication of omega-3 fatty acids. For the remaining psychiatric disturbances, including autism spectrum disorders, anxiety disorders, obsessive-compulsive disorder, eating disorders and substance use disorder, the data are too scarce to draw any conclusion. Concerning tolerability, several studies concluded that omega-3 can be considered safe and well tolerated at doses up to 5 g/day.

Indexed as

attention deficit hyperactivity disorderborderline personality disordereating disordersmood disordersomega-3 fatty acidspolyunsaturated fatty acidsschizophreniasubstance use disordertolerability

Identifiers

PMID27472373
PMCPMC4999787
OpenAlexW2492567170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.